olmesartan has been researched along with Diabetic Glomerulosclerosis in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 22 (62.86) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Abo El-Nasr, NME; Hashad, IM; Saleh, DO | 1 |
| Chatzikyrkou, C; Haller, H; Korda, A; Menne, JJ; Scurt, FG | 1 |
| Chan, JC; Haneda, M; Harada, A; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T | 1 |
| Abe, M; Oikawa, O; Okada, K; Soma, M | 1 |
| Chen, J; Chen, M; Gu, J; He, L; Hu, H; Jing, Y; Li, L; Mei, C; Mei, S; Qi, N; Song, S; Sun, L; Wu, M; Wüthrich, RP; Yang, M | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| Iwamoto, Y; Maekawa, Y; Ohishi, M; Ohnishi, M; Rakugi, H; Shiota, A; Takeda, M; Tatara, Y; Yamamoto, K | 1 |
| Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y | 1 |
| Bakris, G; Haller, H; Izzo, J; Oparil, S; Ruilope, L; Sowers, J; Waeber, B; Weber, M | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Mimran, A; Rabelink, AJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G | 1 |
| Chen, JF; Li, HW; Song, HF; Sun, NL | 1 |
| Ritz, E | 1 |
| de Zeeuw, D; Heerspink, HJ; Roscioni, SS | 1 |
| Ando, K; Fujita, T; Haneda, M; Ito, S; Kashihara, N; Kishimoto, J; Nangaku, M; Node, K; Shimosawa, T | 1 |
| Abe, M; Maruyama, N; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
| Imada, T; Iwasaka, T; Jo, F; Jo, H; Kosaki, A; Kusabe, M; Morimoto, S; Morita, T; Nakahigashi, M; Nishikawa, M; Someya, K; Toyoda, N | 1 |
| Hayashi, K | 1 |
| Arumugam, S; Giridharan, VV; Kodama, M; Lakshmanan, AP; Meilei, H; Sari, FR; Soetikno, V; Sukumaran, V; Suzuki, K; Thandavarayan, RA; Watanabe, K | 1 |
| Fujita, E; Higo, S; Hirama, A; Iino, Y; Kaneko, T; Katayama, Y; Mii, A; Mishina, M; Ueda, K; Utsumi, K; Watanabe, Y; Yasuda, F | 1 |
| Chan, JC; Haneda, M; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T | 1 |
| Imai, E | 1 |
| Kumagai, H; Matsubara, H; Oda, T; Ohshima, N; Senda, M; Tadano, H; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Chetsurakarn, S; Eiam-Ong, S; Limkuansuwan, P; Manotham, K; Ongvilawan, B; Tanamai, J; Tungsanga, K; Urusopone, P | 1 |
| Chatzikyrkou, C; Menne, J | 1 |
| Haller, H; Menne, J; Ritz, E | 1 |
| Schmieder, RE | 1 |
| Halimi, S | 1 |
| Pugsley, MK | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Mimran, A; Rabelink, AJ; Remuzzi, G; Ritz, E; Ruilope, LM; Rump, LC; Viberti, GC | 1 |
| Abe, H; Arai, H; Doi, T; Fukatsu, A; Iehara, N; Kanamori, H; Kita, T; Matsubara, T; Mima, A; Nagai, K; Sumi, E; Takahashi, T | 1 |
| Chan, JC; Haneda, M; Imai, E; Ito, S; Makino, H | 1 |
| Higashi, K; Hyodo, N; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Oda, T; Suzuki, S; Yamada, M; Yamamoto, K | 1 |
| Abe, H; Arai, H; Araki, M; Doi, T; Fukatsu, A; Iehara, N; Kanamori, H; Kita, T; Matsubara, T; Matsuura, M; Mima, A; Nagai, K; Takahashi, T; Tamura, Y; Tominaga, T; Torikoshi, K | 1 |
| Ito, M; Izuhara, Y; Miyata, T; Ohtomo, S; Van Ypersele De Strihou, C | 1 |
| Kang, JJ; Meer, EJ; Peti-Peterdi, J; Sipos, A; Toma, I; Vargas, SL | 1 |
5 review(s) available for olmesartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Endothelium, Vascular; Humans; Imidazoles; Renin-Angiotensin System; Risk Factors; Tetrazoles | 2010 |
[Recent advance in kidney and hypertension research].
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Agonists; Catheter Ablation; Cerebrovascular Circulation; Chronic Disease; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Imidazoles; Randomized Controlled Trials as Topic; Tetrazoles | 2012 |
[Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Imidazoles; Incidence; Kidney Failure, Chronic; Male; Meta-Analysis as Topic; Metabolic Syndrome; Multicenter Studies as Topic; Placebos; Primary Prevention; Randomized Controlled Trials as Topic; Rats; Rats, Inbred Strains; Risk Factors; Sex Factors; Tetrazoles; Time Factors; Treatment Outcome | 2005 |
The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Desoxycorticosterone; Diabetes Mellitus; Diabetic Nephropathies; Hypertension; Imidazoles; Kidney; Rats; Rats, Inbred SHR; Rats, Zucker; Tetrazoles | 2005 |
10 trial(s) available for olmesartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; Imidazoles; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Regression Analysis; Renin-Angiotensin System; Tetrazoles; Treatment Outcome | 2013 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acid-Binding Proteins; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome | 2010 |
Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Europe; Female; Humans; Hypertension; Hypoglycemic Agents; Imidazoles; Male; Middle Aged; Office Visits; Predictive Value of Tests; Regression Analysis; Risk Assessment; Risk Factors; Tetrazoles; United States; Young Adult | 2011 |
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action
Topics: Adult; Aged; Albuminuria; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Middle Aged; Research Design; Sympatholytics; Tetrazoles | 2011 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2011 |
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hyperkalemia; Hypertension; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Proteinuria; Stroke; Tetrazoles; Treatment Outcome | 2011 |
[Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Imidazoles; Kidney Failure, Chronic; Male; Tetrazoles | 2011 |
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Tetrazoles | 2006 |
Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Asian People; Creatinine; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Imidazoles; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Research Design; Tetrazoles | 2006 |
20 other study(ies) available for olmesartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Role of olmesartan in ameliorating diabetic nephropathy in rats by targeting the AGE/PKC, TLR4/P38-MAPK and SIRT-1 autophagic signaling pathways.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fructose; Imidazoles; Kidney; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats; Signal Transduction; Sirtuins; Streptozocin; Tetrazoles; Toll-Like Receptor 4 | 2022 |
Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Imidazoles; Male; Middle Aged; Outcome Assessment, Health Care; Sex Factors; Tetrazoles | 2020 |
Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Rate; Humans; Imidazoles; Kidney Function Tests; Male; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Renin; Tetrazoles | 2015 |
Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis.
Topics: Albuminuria; Angiotensin II; Animals; Apoptosis; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Imidazoles; Male; Mice; Mice, Inbred Strains; p38 Mitogen-Activated Protein Kinases; Podocytes; Sirtuin 1; Tetrazoles | 2016 |
Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nephrons; Peptidyl-Dipeptidase A; Phenotype; Receptor, Angiotensin, Type 1; Tetrazoles | 2010 |
Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hemodynamics; Imidazoles; Kidney; Male; Organ Size; Rats; Rats, Wistar; Tetrazoles | 2011 |
Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Imidazoles; Randomized Controlled Trials as Topic; Tetrazoles | 2011 |
Diabetes: ROADMAP: the road to renoprotection?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazoles; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Treatment Outcome | 2011 |
Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Imidazoles; Male; Mice; Oxidative Stress; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 2011 |
L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Male; Tetrazoles | 2011 |
Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Activation; Gene Expression; Imidazoles; Intracellular Signaling Peptides and Proteins; Kidney; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peptidyl-Dipeptidase A; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Tetrazoles | 2012 |
Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Female; Humans; Imidazoles; Imidazolidines; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; P-Selectin; Tetrazoles | 2012 |
Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study.
Topics: Adult; Angiotensin Receptor Antagonists; Diabetic Nephropathies; Female; Humans; Hypoxia; Imidazoles; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Oxygen; Renal Insufficiency, Chronic; Tetrazoles; Young Adult | 2012 |
Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazoles; Prevalence; Randomized Controlled Trials as Topic; Tetrazoles | 2012 |
["High dosage monotherapy"].
Topics: Animals; Antihypertensive Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Imidazoles; Patient Compliance; Proteinuria; Tetrazoles | 2005 |
Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Butadienes; Cell Line; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression; Glomerular Mesangium; Imidazoles; Male; Mesangial Cells; Nitriles; Phosphorylation; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Signal Transduction; Smad1 Protein; src-Family Kinases; Tetrazoles | 2006 |
A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Enzyme Inhibitors; Glycated Hemoglobin; Imidazoles; Intracellular Signaling Peptides and Proteins; Kidney; Lipid Metabolism; Male; Phosphoprotein Phosphatases; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Rats; Rats, Inbred OLETF; Rho Factor; rho-Associated Kinases; Signal Transduction; Tetrazoles | 2007 |
Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Mesangium; Imidazoles; Kidney; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Smad1 Protein; Tetrazoles | 2008 |
Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetic Nephropathies; Disease Models, Animal; Imidazoles; Kidney; Male; Mice; Mice, Inbred ICR; Mice, Transgenic; Nitric Oxide Synthase Type II; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Serpins; Tetrazoles | 2008 |
The collecting duct is the major source of prorenin in diabetes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Division; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Hypertension, Renal; Imidazoles; Immunohistochemistry; Juxtaglomerular Apparatus; Kidney Tubules, Collecting; Microscopy, Fluorescence; Quinacrine; Rats; Rats, Wistar; Renin; Tetrazoles; Trypsin; Vasoconstrictor Agents | 2008 |